What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Markku Miettinen focuses on Pathology, Immunohistochemistry, GiST, CD34 and CD117.
Many of his studies on Pathology involve topics that are commonly interrelated, such as Stomach.
His studies in Immunohistochemistry integrate themes in fields like Germline mutation, SDHB, Stromal cell and Histopathology.
The GiST study combines topics in areas such as Imatinib and Imatinib mesylate.
In his research on the topic of CD34, Melanoma is strongly related with Metastasis.
His CD117 research is multidisciplinary, incorporating perspectives in Smooth Muscle Tumor, Leiomyosarcoma, Rectum, Gastrointestinal tract and Interstitial cell of Cajal.
His most cited work include:
- Diagnosis of gastrointestinal stromal tumors: A consensus approach. (2625 citations)
- Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. (1456 citations)
- Gastrointestinal stromal tumors: Pathology and prognosis at different sites (1228 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Pathology, Immunohistochemistry, Cancer research, Sarcoma and GiST.
His research combines CD34 and Pathology.
His CD34 research is multidisciplinary, incorporating elements of Leiomyoma and Desmin.
His Immunohistochemistry study deals with Keratin intersecting with Cytokeratin.
His Sarcoma research incorporates themes from Differential diagnosis and Anatomical pathology.
His research in GiST intersects with topics in Imatinib and Oncology.
He most often published in these fields:
- Pathology (79.64%)
- Immunohistochemistry (25.95%)
- Cancer research (15.52%)
What were the highlights of his more recent work (between 2013-2021)?
- Pathology (79.64%)
- Cancer research (15.52%)
- Immunohistochemistry (25.95%)
In recent papers he was focusing on the following fields of study:
Markku Miettinen spends much of his time researching Pathology, Cancer research, Immunohistochemistry, Internal medicine and Cancer.
The study of Pathology is intertwined with the study of SDHB in a number of ways.
His Cancer research study combines topics from a wide range of disciplines, such as Mutation, Germline mutation, Somatic cell, Fusion gene and Epigenetics.
His Immunohistochemistry study integrates concerns from other disciplines, such as Mesothelioma, Lymph node, Differential diagnosis, KRAS and Adenocarcinoma.
His Internal medicine research incorporates elements of Gastroenterology, Endocrinology, Oncology and Hereditary diffuse gastric cancer.
Markku Miettinen focuses mostly in the field of GiST, narrowing it down to matters related to Stromal tumor and, in some cases, PDGFRA.
Between 2013 and 2021, his most popular works were:
- The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation (220 citations)
- Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. (171 citations)
- Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. (148 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Markku Miettinen mostly deals with Pathology, Immunohistochemistry, Cancer research, Germline mutation and Sarcoma.
His Pathology research includes themes of Germ cell tumors, CD34 and Cancer.
His CD99 study, which is part of a larger body of work in CD34, is frequently linked to Context, bridging the gap between disciplines.
The concepts of his Immunohistochemistry study are interwoven with issues in Sanger sequencing, Lung and PDGFRA.
His biological study spans a wide range of topics, including KRAS, Neuroblastoma RAS viral oncogene homolog, Topoisomerase, Methyltransferase and Adenocarcinoma.
His study explores the link between Sarcoma and topics such as Fusion gene that cross with problems in Nucleolus, Chromosomal translocation and Stroma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
